{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:44:48Z","timestamp":1792802688170,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annalsthoracicsurgery.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Annals of Thoracic Surgery"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.athoracsur.2018.02.030","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T14:05:09Z","timestamp":1521381909000},"page":"178-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors"],"prefix":"10.1016","volume":"106","author":[{"given":"Matthew J.","family":"Bott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Cools-Lartigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay See","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Dycoco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjit S.","family":"Bains","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Isbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Molena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie W.","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Sihag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.athoracsur.2018.02.030_bib1","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2018.02.030_bib2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1200\/JCO.2017.72.2850","article-title":"Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study","volume":"36","author":"Callahan","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2018.02.030_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2018.02.030_bib4","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2018.02.030_bib5","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2018.02.030_bib6","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.athoracsur.2017.03.038","article-title":"Initial experience with lung cancer resection after treatment with t-cell checkpoint inhibitors","volume":"104","author":"Chaft","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2018.02.030_bib7","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/j.jtho.2017.08.017","article-title":"Complete response achieved 1 year after a single administration of nivolumab in a patient with lung adenocarcinoma with negative expression of PD-11","volume":"12","author":"Iwata","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2018.02.030_bib8","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1245\/s10434-013-2999-1","article-title":"Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma","volume":"20","author":"Gyorki","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.athoracsur.2018.02.030_bib9","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2018.02.030_bib10","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1158\/1078-0432.CCR-17-3269","article-title":"Beyond concurrent chemoradiation: the emerging role of PD-1\/PD-L1 inhibitors in stage III lung cancer","volume":"24","author":"McCall","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.athoracsur.2018.02.030_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"issue":"Suppl 1","key":"10.1016\/j.athoracsur.2018.02.030_bib12","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis","volume":"6","author":"Hu","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.athoracsur.2018.02.030_bib13","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2018.02.030_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.athoracsur.2018.02.030_bib15","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid\u00a0dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.athoracsur.2018.02.030_bib16","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1097\/JTO.0b013e318228a0d8","article-title":"Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases","volume":"6","author":"Barnett","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2018.02.030_bib17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.athoracsur.2006.02.051","article-title":"Thoracoscopic lobectomy: a safe and effective strategy for patients receiving induction therapy for non-small cell lung cancer","volume":"82","author":"Petersen","year":"2006","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2018.02.030_bib18","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.21037\/jtd.2016.07.09","article-title":"Perioperative outcomes and lymph node assessment after induction therapy in patients with clinical N1 or N2 non-small cell lung cancer","volume":"8","author":"Glover","year":"2016","journal-title":"J\u00a0Thorac Dis"}],"container-title":["The Annals of Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497518303448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497518303448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T03:53:26Z","timestamp":1757735606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003497518303448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0003497518303448"],"URL":"https:\/\/doi.org\/10.1016\/j.athoracsur.2018.02.030","relation":{},"ISSN":["0003-4975"],"issn-type":[{"value":"0003-4975","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors","name":"articletitle","label":"Article Title"},{"value":"The Annals of Thoracic Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athoracsur.2018.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The Society of Thoracic Surgeons Published by Elsevier","name":"copyright","label":"Copyright"}]}}